


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

PROFIT WARNING

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Insilico Medicine**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 and information currently available to the Company, the Group is expected to record (i) a revenue in the range of approximately USD55.8 million to approximately USD56.3 million for the year ended December 31, 2025, as compared to a revenue of approximately USD85.8 million for the year ended December 31, 2024; and (ii) a loss attributable to the owners of the Company in the range of approximately USD352.1 million to approximately USD355.8 million for the year ended December 31, 2025, as compared to a loss attributable to the owners of the Company of approximately USD17.1 million for the year ended December 31, 2024.

The expected increase in loss attributable to the owners of the Company was mainly due to the (i) approximately USD296.7 million loss from changes in fair value of redeemable convertible preferred shares (which is non-recurring and non-cash in nature); and (ii) revenue decline in the range of approximately USD29.5 million to approximately USD30.0 million. There is a decrease in the Company’s pipeline development revenue for the year ended December 31, 2025. The pipeline development revenue from upfront payments in 2025 in the range of approximately USD15.0 million to USD15.3 million is comparably lower than 2024 (2024: USD58.0 million).

The Board considers that the presentation of adjusted loss (non-IFRS measures) would facilitate comparisons of operating performance from period to period and company to company. The adjusted loss (non-IFRS measures) is defined as loss for the year adjusted by adding back (i) loss or gain from changes in fair value of financial liabilities at fair value through profit or loss, (ii) share-based compensation expenses and (iii) listing expenses. The Group is expected to record an adjusted loss (non-IFRS measures) for the year ended December 31, 2025 in the range of approximately USD43.6 million to approximately USD47.3 million, as compared to an adjusted loss (non-IFRS measures) of approximately USD22.7 million for the year ended December 31, 2024. The increase in the adjusted loss was mainly due to the decline in revenue for the reasons stated above which is partially offset by the decrease in research and development expenses.

The Company is still in the process of finalizing its annual results of the Group for the year ended December 31, 2025. The information contained in this announcement is solely based on a preliminary assessment by the Board with reference to the unaudited consolidated management accounts and information currently available, which have not been audited or reviewed by the auditor or the audit committee of the Company, and are subject to adjustments where necessary. Shareholders and potential investors of the Company should refer to and carefully read the annual results announcement of the Company for the year ended December 31, 2025, which is expected to be published in March 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, March 6, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.